Related Experiment Video

Updated: Nov 16, 2025

High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts
06:06

High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts

Published on: December 20, 2024

921

Androgen Receptor and PIM1 Expression in Tumor Tissue of Patients With Triple-negative Breast Cancer

Aliki Ntzifa1, Areti Strati1, Georgia-Angeliki Koliou2

  • 1Analysis of Circulating Tumor Cells Laboratory, Laboratory of Analytical Chemistry, Department of Chemistry, University of Athens, Athens, Greece.

Cancer Genomics & Proteomics
|February 20, 2021
PubMed
Abstract

Insights

Androgen receptor (AR) and PIM1 kinase co-expression is rare in triple-negative breast cancer (TNBC). This study found no significant prognostic value for AR or PIM1 in TNBC patient survival.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Triple-negative breast cancer (TNBC) lacks effective targeted therapies.
  • Androgen receptor (AR) and PIM1 kinase are implicated in a subset of TNBC.
  • PIM1 kinases regulate AR transcriptional activity, independent of androgens.

Purpose of the Study:

  • To evaluate the expression of AR and PIM1 in TNBC.
  • To determine the prognostic significance of AR and PIM1 in TNBC.

Main Methods:

  • Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was used.
  • AR and PIM1 transcripts were measured in formalin-fixed paraffin-embedded tumor samples.
  • 141 TNBC patients were included in the study.

Main Results:

  • AR was expressed in 38.3% of TNBC cases.
  • PIM1 was expressed in 10.6% of TNBC cases.
  • Co-expression of AR and PIM1 was found in only 5.0% of patients (7/141).
  • Neither AR nor PIM1 expression showed prognostic significance for overall or disease-free survival.

Conclusions:

  • Co-expression of AR and PIM1 is infrequent in TNBC.
  • Further research in larger cohorts is needed to explore the therapeutic implications of AR and PIM1 in TNBC management.
Keywords:
PIM1RT-qPCRTriple-negative breast cancerandrogen receptor

More Related Videos

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.2K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

15.1K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.1K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.6K